Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | APVO436 |
| Synonyms | |
| Therapy Description |
APVO436 is a T-cell engager comprising a bispecific antibody targeting IL3RA (CD123) on tumor cells and CD3 on T-cells, which potentially induces antitumor immune activity (PMID: 34439266). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| APVO436 | APVO-436|APVO 436|Mipletamig | CD123 (IL3RA) Antibody 14 CD3 Antibody 119 | APVO436 is a T-cell engager comprising a bispecific antibody targeting IL3RA (CD123) on tumor cells and CD3 on T-cells, which potentially induces antitumor immune activity (PMID: 34439266). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|